Heat Biologics provides clinical and business update
Heat Biologics announced the phase 2 trial has expanded to evaluate the benefit of HS-110 in combination with a different anti-PD-1 checkpoint inhibitor to treat patients earlier in the course of their metastatic disease. January 10, 2019